Transition from Ambrisentan to Bosentan in Pulmonary Arterial Hypertension: A Single-Center Prospective Study
Background and objective: Two endothelin receptor antagonists (ETRAs), bosentan and ambrisentan, are approved for patients with pulmonary arterial hypertension (PAH). However, there is little information about the transition strategy between these two ETRAs. We aimed to evaluate the safety and effic...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-01-01
|
| Series: | Canadian Respiratory Journal |
| Online Access: | http://dx.doi.org/10.1155/2018/9836820 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832556312100077568 |
|---|---|
| author | Su-Gang Gong Lan Wang Bigyan Pudasaini Ping Yuan Rong Jiang Qin-Hua Zhao Jing He Rui Zhang Wen-hui Wu Jin-Ming Liu Cai-cun Zhou |
| author_facet | Su-Gang Gong Lan Wang Bigyan Pudasaini Ping Yuan Rong Jiang Qin-Hua Zhao Jing He Rui Zhang Wen-hui Wu Jin-Ming Liu Cai-cun Zhou |
| author_sort | Su-Gang Gong |
| collection | DOAJ |
| description | Background and objective: Two endothelin receptor antagonists (ETRAs), bosentan and ambrisentan, are approved for patients with pulmonary arterial hypertension (PAH). However, there is little information about the transition strategy between these two ETRAs. We aimed to evaluate the safety and efficacy from ambrisentan to bosentan. Methods: Twenty PAH patients were enrolled into the single-center, open-labelled prospective study. Echocardiogram, WHO functional class (WHO-FC), 6-minute walking distance (6MWD), right heart catheterization, and hemotology were collected. After receiving oral 5 mg ambrisentan daily initially for one year, the patients were divided into two arms: eight patients switched to bosentan, while the remaining 12 patients continued ambrisentan. Characteristics at baseline, 1-and 2-year follow-up points were compared. Results: There were no significant differences in echocardiogram, WHO-FC, hemodynamics, demographics and liver function at baseline, 1-and 2-year points in both arms. 6MWD in bosentan group was significantly shorter at baseline. But there were no significant differences of 6MWD at 1- and 2-year points. Conclusions: It is safe for stable PAH patients to transition from ambrisentan to bosentan without hemodynamic or hematologic deterioration. |
| format | Article |
| id | doaj-art-0eda9ccd99524a759332c7cdf4eaee33 |
| institution | Kabale University |
| issn | 1198-2241 1916-7245 |
| language | English |
| publishDate | 2018-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Canadian Respiratory Journal |
| spelling | doaj-art-0eda9ccd99524a759332c7cdf4eaee332025-02-03T05:45:44ZengWileyCanadian Respiratory Journal1198-22411916-72452018-01-01201810.1155/2018/98368209836820Transition from Ambrisentan to Bosentan in Pulmonary Arterial Hypertension: A Single-Center Prospective StudySu-Gang Gong0Lan Wang1Bigyan Pudasaini2Ping Yuan3Rong Jiang4Qin-Hua Zhao5Jing He6Rui Zhang7Wen-hui Wu8Jin-Ming Liu9Cai-cun Zhou10Department of Cardio-Pulmonary Circulation, The Third Affiliated Hospital of Soochow University, Shanghai Pulmonary Hospital, Suzhou, Jiangsu 215000, ChinaDepartment of Cardio-Pulmonary Circulation, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, ChinaDepartment of Cardio-Pulmonary Circulation, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, ChinaDepartment of Cardio-Pulmonary Circulation, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, ChinaDepartment of Cardio-Pulmonary Circulation, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, ChinaDepartment of Cardio-Pulmonary Circulation, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, ChinaDepartment of Cardio-Pulmonary Circulation, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, ChinaDepartment of Cardio-Pulmonary Circulation, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, ChinaDepartment of Cardio-Pulmonary Circulation, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, ChinaDepartment of Cardio-Pulmonary Circulation, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, ChinaDepartment of Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, ChinaBackground and objective: Two endothelin receptor antagonists (ETRAs), bosentan and ambrisentan, are approved for patients with pulmonary arterial hypertension (PAH). However, there is little information about the transition strategy between these two ETRAs. We aimed to evaluate the safety and efficacy from ambrisentan to bosentan. Methods: Twenty PAH patients were enrolled into the single-center, open-labelled prospective study. Echocardiogram, WHO functional class (WHO-FC), 6-minute walking distance (6MWD), right heart catheterization, and hemotology were collected. After receiving oral 5 mg ambrisentan daily initially for one year, the patients were divided into two arms: eight patients switched to bosentan, while the remaining 12 patients continued ambrisentan. Characteristics at baseline, 1-and 2-year follow-up points were compared. Results: There were no significant differences in echocardiogram, WHO-FC, hemodynamics, demographics and liver function at baseline, 1-and 2-year points in both arms. 6MWD in bosentan group was significantly shorter at baseline. But there were no significant differences of 6MWD at 1- and 2-year points. Conclusions: It is safe for stable PAH patients to transition from ambrisentan to bosentan without hemodynamic or hematologic deterioration.http://dx.doi.org/10.1155/2018/9836820 |
| spellingShingle | Su-Gang Gong Lan Wang Bigyan Pudasaini Ping Yuan Rong Jiang Qin-Hua Zhao Jing He Rui Zhang Wen-hui Wu Jin-Ming Liu Cai-cun Zhou Transition from Ambrisentan to Bosentan in Pulmonary Arterial Hypertension: A Single-Center Prospective Study Canadian Respiratory Journal |
| title | Transition from Ambrisentan to Bosentan in Pulmonary Arterial Hypertension: A Single-Center Prospective Study |
| title_full | Transition from Ambrisentan to Bosentan in Pulmonary Arterial Hypertension: A Single-Center Prospective Study |
| title_fullStr | Transition from Ambrisentan to Bosentan in Pulmonary Arterial Hypertension: A Single-Center Prospective Study |
| title_full_unstemmed | Transition from Ambrisentan to Bosentan in Pulmonary Arterial Hypertension: A Single-Center Prospective Study |
| title_short | Transition from Ambrisentan to Bosentan in Pulmonary Arterial Hypertension: A Single-Center Prospective Study |
| title_sort | transition from ambrisentan to bosentan in pulmonary arterial hypertension a single center prospective study |
| url | http://dx.doi.org/10.1155/2018/9836820 |
| work_keys_str_mv | AT suganggong transitionfromambrisentantobosentaninpulmonaryarterialhypertensionasinglecenterprospectivestudy AT lanwang transitionfromambrisentantobosentaninpulmonaryarterialhypertensionasinglecenterprospectivestudy AT bigyanpudasaini transitionfromambrisentantobosentaninpulmonaryarterialhypertensionasinglecenterprospectivestudy AT pingyuan transitionfromambrisentantobosentaninpulmonaryarterialhypertensionasinglecenterprospectivestudy AT rongjiang transitionfromambrisentantobosentaninpulmonaryarterialhypertensionasinglecenterprospectivestudy AT qinhuazhao transitionfromambrisentantobosentaninpulmonaryarterialhypertensionasinglecenterprospectivestudy AT jinghe transitionfromambrisentantobosentaninpulmonaryarterialhypertensionasinglecenterprospectivestudy AT ruizhang transitionfromambrisentantobosentaninpulmonaryarterialhypertensionasinglecenterprospectivestudy AT wenhuiwu transitionfromambrisentantobosentaninpulmonaryarterialhypertensionasinglecenterprospectivestudy AT jinmingliu transitionfromambrisentantobosentaninpulmonaryarterialhypertensionasinglecenterprospectivestudy AT caicunzhou transitionfromambrisentantobosentaninpulmonaryarterialhypertensionasinglecenterprospectivestudy |